Comparative Pharmacology
Head-to-head clinical analysis: MERCAPTOPURINE versus PYQUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERCAPTOPURINE versus PYQUVI.
MERCAPTOPURINE vs PYQUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mercaptopurine is a prodrug that is converted to 6-thioguanine nucleotides, which inhibit de novo purine synthesis and DNA replication by incorporating into DNA and RNA. It also inhibits purine nucleotide interconversions via feedback inhibition of amidophosphoribosyltransferase.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
1.5 to 2.5 mg/kg orally once daily; maintenance 1.5 to 2.5 mg/kg orally once daily.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateMercaptopurine + Digoxin
"Mercaptopurine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMercaptopurine + Digitoxin
"Mercaptopurine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMercaptopurine + Deslanoside
"Mercaptopurine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMercaptopurine + Acetyldigitoxin
"Mercaptopurine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 1.5-3 hours (variable); for active metabolites (e.g., 6-thioguanine nucleotides) half-life is 5-7 days, which correlates with myelosuppression.
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Renal: 20-30% as unchanged drug; biliary/fecal: minor; extensive hepatic metabolism to active and inactive metabolites.
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Category D/X
Category C
Antimetabolite
Antimetabolite